Q&A: Perioperative immunotherapy advances for early-stage NSCLC
Editor's Note Perioperative immunotherapy is reshaping treatment strategies for early-stage non-small cell lung cancer (NSCLC) without actionable mutations, according to Dr. Roy S. Herbst of Yale Cancer Center. In a recent interview with OncLive, the oncology expert highlighted the promise of neoadjuvant and adjuvant therapies to improve outcomes for these…
Study: Wearable devices improve postoperative physical activity in lung cancer patients
Editor's Note In a recent study, lung cancer patients using wearable devices showed significantly improved postoperative physical activity and pulmonary function as well as reduced symptoms such as dyspnea and pain. Published September 20 in Jama Network Open, the study compared 74 patients in the intervention group (who used wearable…
Study: Adjuvant nivolumab reduces risk of death, lung cancer recurrence
Editor's Note An analysis of two phase-III trials showed adjuvant administration of nivolumab (Opdivo) plus chemotherapy reduces the risk of recurrence or death in patients with resectable non-small cell lung cancer (NSCLC) by 40% compared to neoadjuvant nivolumab plus chemotherapy alone, Medpage Today reported September 9. "With the caveat that…
NYU Langone surgeons complete first fully robotic lung transplant in US
Editor's Note Surgeons at NYU Langone Health used a da Vinci X robotic system throughout an entire lung transplant procedure for the first time in the US and the third time in the world, DotMed reported September 11. Led by Dr. Stephanie Chang, the surgery offered a fast, minimally invasive…
Immunotherapy’s FDA approval expected to improve lung cancer treatment
Editor's Note The US Food & Drug Administration (FDA) has approved immunotherapy durvalumab for perioperative treatment of resectable non-small cell lung cancer (NSCLC), according to an August 15 announcement. The approval is for durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as…
Study: Starting adjuvant chemotherapy more than 6 weeks after surgery worsens colorectal cancer survival
Editor's Note A post hoc analysis of the SCOT phase 3 randomized clinical trial reveals that initiating adjuvant chemotherapy more than 6 weeks after surgery is linked to worse disease-free survival (DFS) in patients with high-risk stage II and stage III colorectal cancer. Published June 12 in JAMA Surgery, the…
American Cancer Society updates lung cancer screening guidelines
Editor's Note The American Cancer Society (ACS) has updated its lung cancer screening recommendations from 2013 in an effort to reduce deaths based on smoking history, CA: A Cancer Journal for Clinicians November 1 reports. According to the updated guidelines, lung cancer is the leading cause of cancer death in…
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference